A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)

Highlights • We reported the application of icotinib in the routine clinical setting. • Favorable tolerability of icotinib was seen in overall population and elder patients. • Icotinib displayed antitumor activities in unselected patients. • More efficacy benefits were documented in EGFR-mutant pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2014-11, Vol.86 (2), p.207-212
Hauptverfasser:	Hu, Xingsheng, Han, Baohui, Gu, Aiqin, Zhang, Yiping, Jiao, Shun Chang, Wang, Chang-li, He, Jintao, Jia, Xueke, Zhang, Li, Peng, Jiewen, Wu, Meina, Ying, Kejing, Wang, Junye, Ma, Kewei, Zhang, Shucai, You, Changxuan, Tan, Fenlai, Wang, Yinxiang, Ding, Lieming, Sun, Yan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Crown Ethers - adverse effects Crown Ethers - therapeutic use efficacy EGFR TKIs Female Hematology, Oncology and Palliative Medicine Humans Icotinib Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Neoplasm Staging Non-small-cell lung cancer Phase IV Pneumology Pulmonary/Respiratory Quinazolines - adverse effects Quinazolines - therapeutic use real-world study Receptor, Epidermal Growth Factor - genetics Retreatment Retrospective Studies Risk Factors safety Treatment Outcome Tumors Tumors of the respiratory system and mediastinum Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We reported the application of icotinib in the routine clinical setting. • Favorable tolerability of icotinib was seen in overall population and elder patients. • Icotinib displayed antitumor activities in unselected patients. • More efficacy benefits were documented in EGFR-mutant patients.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2014.08.014